For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Formats:
Features:
Interleukin-1 Receptor Antagonist (IL1RA) is a member of the interleukin-1 cytokine family. Immune, epithelial, and adipose cells secrete IL1RA which will bind to the interleukin-1 receptor and inhibit pro-inflammatory signaling through IL-1α and IL-1β. Studies have shown that IL1RA plays a key role in suppressing the pro-inflammatory effects of IL-1 in diseases like rheumatoid arthritis. Additionally, it has been observed that IL1RA may play an important role in diseases like osteoporosis where IL1RA levels are suppressed compared to controls. Furthermore, it has been observed that IL-1 cytokines are abundantly present at tumor sites and the addition of IL1RA can suppress growth of IL-1 producing tumors.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Assay Target | IL-1RA |
---|---|
Assay Target Class | Cytokine |
Automation Compatible | Yes |
Detection Method | Alpha |
Experimental Type | In vitro |
Product Brand Name | AlphaLISA |
Shipping Condition | Blue Ice |
Therapeutic Area | Inflammation |
Unit Size | 5,000 assay points |
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.